Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
florbetapir (18F)
- Development stage
- Approved
- Lead developer
- Avid Radiopharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Amyvid (florbetapir F18) is an FDA-approved small-molecule radiopharmaceutical diagnostic agent originally developed by Avid Radiopharmaceuticals (a subsidiary of Eli Lilly). It is a positron emission tomography (PET) imaging tracer that binds with high affinity to beta-amyloid neuritic plaques in the brain, which are a hallmark pathology of Alzheimer's disease. It is indicated for brain PET imaging in cognitively impaired adults being evaluated for Alzheimer's disease and other causes of cognitive decline. Additionally, florbetapir F18 is being investigated in an exploratory clinical study (NCT04390009) sponsored by the Brain Health Alliance for entire-body PET-CT scans to detect and monitor peripheral and central demyelination and remyelination in patients with multiple sclerosis (MS), leveraging its secondary binding affinity to myelin.
- Brand names
- Amyvid
- Other names
- 18F-florbetapirF-18 florbetapirF18 florbetapirF 18 florbetapirF18-florbetapirF-18-florbetapirF 18-florbetapirflorbetapirflorbetapir F 18florbetapir F-18florbetapir F18
02
Targets
MAPT (Microtubule-associated protein tau)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on florbetapir (18F).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on florbetapir (18F).